{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-228185","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2021-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.057108+00:00","generated_at":"2026-06-30T00:55:39.513608+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Kura Oncology appoints Helen Collins, M.D. as Class II director","bullets":["Appointed effective July 28, 2021; term expires at 2022 annual meeting.","Previously EVP and CMO at Five Prime Therapeutics, led bemarituzumab development until Amgen acquisition in April 2021.","Received options for 46,000 shares (3-year vest) and 19,166 shares (1-year vest); annual cash retainer $40,000.","Annual automatic option grants of 23,000 shares on each annual meeting date, vesting over one year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-228185","json":"https://secwatch.observer/filing/0001193125-21-228185.json","markdown":"https://secwatch.observer/filing/0001193125-21-228185.md","text":"https://secwatch.observer/filing/0001193125-21-228185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312521228185/0001193125-21-228185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312521228185/d200489d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T00:55:39.513608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f2121b523a","claim":"Helen Collins, M.D. was appointed as Class II director at Kura Oncology, Inc..","evidence_excerpt":"appointed Helen Collins, M.D. as a Class II director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312521228185/0001193125-21-228185-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}